Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post on LinkedIn:
”Very proud of our two recent clinical trial publications:
ABBV-368 in HNSCC and BLU-451 in lung cancer. Neither program will move forward because of insufficient efficacy.
In drug development, behind every negative study are years of scientific effort, patients’ trust, difficult decisions, and teams who continue exploring forward despite disappointment. Our commitment to defeating cancer is built not only on accelerated approvals, plenary talks, flowers and cakes, but also on unmet endpoints, toxicities, rejections and tears.
To my resilient peer drug developers, and those molecules that will never receive a name: we must go on.”
Other Articles Featuring Xiuning Le on OncoDaily.